Covid-19 and cardiovascular and metabolic disease

Konstantinos et al. SARS-CoV-2 Infection and Obesity: Common Inflammatory and Metabolic Aspects Diabetes Metab Syndr. 2020 Apr 29;14(4):469-471. doi: 10.1016/j.dsx.2020.04.033 https://pubmed.ncbi.nlm.nih.gov/32387864

Fadini et al. Prevalence and Impact of Diabetes Among People Infected With SARS-CoV-2 J Endocrinol Invest. 2020 Jun;43(6):867-869. doi: 10.1007/s40618-020-01236-2. https://pubmed.ncbi.nlm.nih.gov/32222956

Sarah et al. COVID-19 and Diabetes: The Why, the What and the How J Diabetes Complications. 2020 May 22;107637.doi: 10.1016/j.jdiacomp.2020.107637. https://pubmed.ncbi.nlm.nih.gov/32456846

Xue et al. High Expression of ACE2 on the Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2 J Invest Dermatol. 2020 May 23;S0022-202X(20)31602-X.doi: 10.1016/j.jid.2020.05.087. https://pubmed.ncbi.nlm.nih.gov/32454066

Cecilia et al. SARS-CoV-2 and Diabetes: New Challenges for the Disease Diabetes Res Clin Pract. 2020 May 21;108228. doi: 10.1016/j.diabres.2020.108228. https://pubmed.ncbi.nlm.nih.gov/32446801

Marko et al. Diabetes and Metabolic Syndrome as Risk Factors for COVID-19 Diabetes Metab Syndr. 2020 May 8;14(4):671-677.doi: 10.1016/j.dsx.2020.05.013. https://pubmed.ncbi.nlm.nih.gov/32438331

Sheen et al. [Obesity and Risk of Severe COVID-19] Rev Med Suisse. 2020 May 27;16(695):1115-1119.https://pubmed.ncbi.nlm.nih.gov/32462841 

Ying et al. COVID-19 and the Cardiovascular System Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095524/

Sonja et al. SARS-CoV-2 Receptor ACE2-dependent Implications on the Cardiovascular System: From Basic Science to Clinical Implications J Mol Cell Cardiol. 2020 Apr 30;144:47-53. doi: 10.1016/j.yjmcc.2020.04.031. https://pubmed.ncbi.nlm.nih.gov/32360703

J. Martín et al. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19 Mayo Clin Proc. 2020 Apr 28;S0025-6196(20)30398-0. doi: 10.1016/j.mayocp.2020.04.028 https://pubmed.ncbi.nlm.nih.gov/32448590

Mariajana et al. COVID-19, Hypertension and Cardiovascular Diseases: Should We Change the Therapy? Pharmacol Res. 2020 May 13;158:104906. doi: 10.1016/j.phrs.2020.104906. https://pubmed.ncbi.nlm.nih.gov/32461198

J. Martin Bos. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19 Mayo Clin Proc. 2020 Apr 28;S0025-6196(20)30398-0.doi: 10.1016/j.mayocp.2020.04.028. https://pubmed.ncbi.nlm.nih.gov/32448590

Böhm et al. Coronavirus Disease 2019 (COVID-19) and Its Implications for Cardiovascular Care: Expert Document From the German Cardiac Society and the World Heart Federation Clin Res Cardiol. 2020 May 27 doi: 10.1007/s00392-020-01656-3. https://pubmed.ncbi.nlm.nih.gov/32462267

Hendre et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020 Apr 16. doi: 10.1161/CIRCULATIONAHA.120.047349. https://www.ncbi.nlm.nih.gov/pubmed/32297796

Liu et al. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020 Apr 15. doi: 10.1161/CIRCULATIONAHA.120.047549. https://www.ncbi.nlm.nih.gov/pubmed/32293910

Marijana et al. COVID-19, Hypertension and Cardiovascular Diseases: Should We Change the Therapy? Pharmacol Res. 2020 May 13;158:104906.doi: 10.1016/j.phrs.2020.104906. https://pubmed.ncbi.nlm.nih.gov/32461198

Li et al. Cardiovascular Disease Potentially Contributes to the Progression and Poor Prognosis of COVID-19 Nutr Metab Cardiovasc Dis. 2020 Apr 18;S0939-4753(20)30134-4. https://pubmed.ncbi.nlm.nih.gov/32456948

Hendre et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020 Apr 16. doi: 10.1161/CIRCULATIONAHA.120.047349. https://www.ncbi.nlm.nih.gov/pubmed/32297796

Liu et al. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020 Apr 15. doi: 10.1161/CIRCULATIONAHA.120.047549. https://www.ncbi.nlm.nih.gov/pubmed/32293910

Fried et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047164

Guo J et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1. https://www.ncbi.nlm.nih.gov/pubmed/32233755

Hill et al. Commentary: COVID-19 in Patients with Diabetes. Metabolism. 2020 Mar 24:154217. doi: 10.1016/j.metabol.2020.154217.  https://www.ncbi.nlm.nih.gov/pubmed/32220611

Gup et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1017. https://www.ncbi.nlm.nih.gov/pubmed/32219356

Huang et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. https://www.ncbi.nlm.nih.gov/pubmed/31986264

Elkind et al. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 Mar 17. doi: 10.1161/CIRCULATIONAHA.120.046749. https://www.ncbi.nlm.nih.gov/pubmed/32181680

Zhou et al. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020 Mar 24;107:154216. doi: 10.1016/j.metabol.2020.154216.  https://www.ncbi.nlm.nih.gov/pubmed/32220612

South et al. COVID-19, ACE2 and the Cardiovascular Consequences. Am J Physiol Heart Circ Physiol. 2020 Mar 31. doi: 10.1152/ajpheart.00217.2020. https://www.ncbi.nlm.nih.gov/pubmed/32228252

Felix Kwenandar. Coronavirus Disease 2019 and Cardiovascular System: A Narrative Review. Int J Cardiol Heart Vasc. 2020 Jun 3;29:100557.doi:10.1016/j.ijcha.2020.100557. eCollection 2020 Aug.

PMID: 32550259

Wassim et al. Endotheliitis and Endothelial Dysfunction in Patients With COVID-19: Its Role in Thrombosis and Adverse Outcomes. J Clin Med. 2020 Jun 15;9(6):E1862.

PMID: 32549229 DOI: 10.3390/jcm9061862

Hamideh Amifarkhryan et al. Outbreak of SARS-CoV2: Pathogenesis of Infection and Cardiovascular Involvement. Hellenic J Cardiol. 2020 Jun 6;S1109-9666(20)30096-8.

PMID: 32522617 PMCID: PMC7275139 DOI: 10.1016/j.hjc.2020.05.007

Jolanda Sabatino et al. COVID-19 and Congenital Heart Disease: Results From a Nationwide Survey. J Clin Med. 2020 Jun 8;9(6):E1774.

PMID: 32521643 DOI: 10.3390/jcm9061774

Daniel antwi et al. Management of Hypertension in COVID-19. World J Cardiol . 2020 May 26;12(5):228-230.

PMID: 32547717 PMCID: PMC7283999 DOI: 10.4330/wjc.v12.i5.228

Maki Komiyama et al. Dilated Cardiomyopathy Risk in Patients With Coronavirus Disease 2019: How to Identify and Characterise It Early? Eur Cardiol. 2020 May 27;15:e49.

PMID: 32536978 PMCID: PMC7277785 DOI: 10.15420/ecr.2020.17

Surma et al. Coronavirus SARS-Cov-2 and Arterial Hypertension – Facts and Myths. Pol Merkur Lekarski. 2020 Jun 17;48(285):195-198.

PMID: 32564046

Khera et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With Coronavirus Disease-19. medRxiv. 2020 May 19;2020.05.17.20104943

PMID: 32511481 PMCID: PMC7273249 DOI: 10.1101/2020.05.17.20104943

Radenkovic et al. Cholesterol in Relation to COVID-19: Should We Care About It? J Clin Med. 2020 Jun 18;9(6):E1909.

PMID: 32570882 DOI: 10.3390/jcm9061909